Refractory relapsing polychondritis: challenges and solutions
Fernando Kemta Lekpa,1,2 Xavier Chevalier3 1Faculty of Health Sciences, University of Buea, Buea, 2Reheumatology Unit, Internal Medicine Department, General Hospital, Douala, Cameroon; 3Department of Rheumatology, Henri Mondor Hospital, University Paris 12, Créteil, France Abstract: Relap...
Guardado en:
Autores principales: | , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/63677202d3d6433b817746197d7efcc5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:63677202d3d6433b817746197d7efcc5 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:63677202d3d6433b817746197d7efcc52021-12-02T07:43:48ZRefractory relapsing polychondritis: challenges and solutions1179-156Xhttps://doaj.org/article/63677202d3d6433b817746197d7efcc52018-01-01T00:00:00Zhttps://www.dovepress.com/refractory-relapsing-polychondritis-challenges-and-solutions-peer-reviewed-article-OARRRhttps://doaj.org/toc/1179-156XFernando Kemta Lekpa,1,2 Xavier Chevalier3 1Faculty of Health Sciences, University of Buea, Buea, 2Reheumatology Unit, Internal Medicine Department, General Hospital, Douala, Cameroon; 3Department of Rheumatology, Henri Mondor Hospital, University Paris 12, Créteil, France Abstract: Relapsing polychondritis is a severe systemic immune-mediated disease characterized by an episodic and progressive inflammatory condition with progressive destruction of cartilaginous structures. This disease has for nearly a century kept secrets not yet explained. The real incidence and prevalence of this rare disease are unknown. The multiple clinical presentations and episodic nature of relapsing polychondritis cause a significant diagnosis delay. No guidelines for the management of patients with relapsing polychondritis have been validated to date. The challenges remain, both in the understanding of its pathophysiology and diagnosis, evaluation of its activity and prognosis, and its treatment. Possible solutions involve the sharing of data for relapsing polychondritis from worldwide reference centers. Thus, we would be able to evolve toward a better knowledge of its pathophysiology, the publication of new diagnosis criteria, which will include biological markers and imaging findings, the prediction of life-threatening or organ-threatening situations, and the publication of therapeutic evidence-based guidelines after performing at randomized controlled trials. Keywords: relapsing polychondritis, diagnosis, criteria, disease activity, treatments, biologicsKemta Lekpa FChevalier XDove Medical PressarticleRelapsing polychondritisDiagnosisCriteriaDisease activityBiologicsDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol Volume 10, Pp 1-11 (2018) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Relapsing polychondritis Diagnosis Criteria Disease activity Biologics Diseases of the musculoskeletal system RC925-935 |
spellingShingle |
Relapsing polychondritis Diagnosis Criteria Disease activity Biologics Diseases of the musculoskeletal system RC925-935 Kemta Lekpa F Chevalier X Refractory relapsing polychondritis: challenges and solutions |
description |
Fernando Kemta Lekpa,1,2 Xavier Chevalier3 1Faculty of Health Sciences, University of Buea, Buea, 2Reheumatology Unit, Internal Medicine Department, General Hospital, Douala, Cameroon; 3Department of Rheumatology, Henri Mondor Hospital, University Paris 12, Créteil, France Abstract: Relapsing polychondritis is a severe systemic immune-mediated disease characterized by an episodic and progressive inflammatory condition with progressive destruction of cartilaginous structures. This disease has for nearly a century kept secrets not yet explained. The real incidence and prevalence of this rare disease are unknown. The multiple clinical presentations and episodic nature of relapsing polychondritis cause a significant diagnosis delay. No guidelines for the management of patients with relapsing polychondritis have been validated to date. The challenges remain, both in the understanding of its pathophysiology and diagnosis, evaluation of its activity and prognosis, and its treatment. Possible solutions involve the sharing of data for relapsing polychondritis from worldwide reference centers. Thus, we would be able to evolve toward a better knowledge of its pathophysiology, the publication of new diagnosis criteria, which will include biological markers and imaging findings, the prediction of life-threatening or organ-threatening situations, and the publication of therapeutic evidence-based guidelines after performing at randomized controlled trials. Keywords: relapsing polychondritis, diagnosis, criteria, disease activity, treatments, biologics |
format |
article |
author |
Kemta Lekpa F Chevalier X |
author_facet |
Kemta Lekpa F Chevalier X |
author_sort |
Kemta Lekpa F |
title |
Refractory relapsing polychondritis: challenges and solutions |
title_short |
Refractory relapsing polychondritis: challenges and solutions |
title_full |
Refractory relapsing polychondritis: challenges and solutions |
title_fullStr |
Refractory relapsing polychondritis: challenges and solutions |
title_full_unstemmed |
Refractory relapsing polychondritis: challenges and solutions |
title_sort |
refractory relapsing polychondritis: challenges and solutions |
publisher |
Dove Medical Press |
publishDate |
2018 |
url |
https://doaj.org/article/63677202d3d6433b817746197d7efcc5 |
work_keys_str_mv |
AT kemtalekpaf refractoryrelapsingpolychondritischallengesandsolutions AT chevalierx refractoryrelapsingpolychondritischallengesandsolutions |
_version_ |
1718399227289141248 |